Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: A portable cryogenic applicator includes a vessel for liquid nitrogen to deliver liquid nitrogen for treatment of skin surfaces using the rotating roller from porous biocompatible material. The cryogenic applicator includes a capillary U-bend to prevent spontaneous discharge of liquid nitrogen through the capillary system to the roller during filling or refilling the cryogenic applicator with liquid nitrogen. The cryogenic applicator also includes a vacuum valve that produce an insulating vacuum environment in a vacuum cavity to prevent heat transfer between the vessel for liquid nitrogen and a vacuum casing, which allows the external surface of the cryogenic applicator to be maintained at ambient temperature. The cryogenic applicator may include a control valve for regulating and maintaining the working pressure in the vessel for liquid nitrogen sufficient to deliver liquid nitrogen through the capillary system and the porous roller body to the surface skin of a patient.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis.

Abstract: A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis.

Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.

Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.

Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.

Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.